Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Apr;53(4):1476-81.
doi: 10.1128/AAC.01141-08. Epub 2009 Feb 2.

Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia

Affiliations
Randomized Controlled Trial

Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia

Anthony M Nicasio et al. Antimicrob Agents Chemother. 2009 Apr.

Abstract

A population pharmacokinetic model of cefepime was constructed from data from adult critical care patients with ventilator-associated pneumonia (VAP). A total of 32 patients treated with high-dose cefepime, 2 g every 8 h (3-h infusion) or a renal function-adjusted equivalent dose, were randomized into two groups--26 for the initial model and 6 for model validation. Serum samples of cefepime were collected at steady state. Nonparametric adaptive grid population modeling was employed using a two-compartment K(slope) pharmacokinetic model relating the elimination rate constant (K(10)) to renal function, as defined by creatinine clearance (CL(CR)), and central distribution volume (V(1)) to total body weight (TBW). The final model was described by the following equations: K(10) = 0.0027 x CL(CR) + 0.071 h(-1) and V(1) = TBW x 0.21 liter/kg. The median intercompartmental transfer constants K(12) and K(21) were 0.780 h(-1) and 0.472 h(-1), respectively. Using these median parameter estimates, the bias, precision, and coefficient of determination for the initial model were 11.3 microg/ml, 24.0 microg/ml, and 26%, respectively. The independent validation group displayed a bias, precision, and coefficient of determination of -1.64 microg/ml, 17.1 microg/ml, and 62%, respectively. Time-concentration profiles were assessed for various dosing regimens, using 5,000-patient Monte Carlo simulations. Among the regimens, the likelihoods of 2 g every 8 h (3-h infusion) achieving free drug concentrations above the MIC for 50% of the dosing interval were 91.8%, 78.1%, and 50.3% for MICs of 8, 16, and 32 microg/ml, respectively. This study provides a pharmacokinetic model capable of predicting cefepime concentrations in critically ill patients with VAP.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Scatter plot of observed versus predicted cefepime concentrations, using the population pharmacokinetic model with covariates.
FIG. 2.
FIG. 2.
Scatter plot of observed and predicted cefepime concentrations of the validation group, in accordance with the median parameter values of the pharmacokinetic population model.
FIG. 3.
FIG. 3.
PTA for cefepime regimens achieving 50% fT>MIC at various CLCR levels: 50 to 120 ml/min (A), 30 to 49 ml/min (B), 10 to 29 ml/min (C). 0.5 INF, 0.5-h (30-min) infusion; 3h INF and 3 INF, 3-h infusion.

References

    1. Barradell, L. B., and H. M. Bryson. 1994. Cefepime: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drugs 47:471-505. - PubMed
    1. Bhat, S. V., A. Y. Peleg, T. P. Lodise, Jr., K. A. Shutt, B. Capitano, B. A. Potoski, and D. L. Paterson. 2007. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob. Agents Chemother. 51:4390-4395. - PMC - PubMed
    1. Boselli, E., D. Breilh, F. Duflo, M. C. Saux, R. Debon, D. Chassard, and B. Allaouchiche. 2003. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit. Care Med. 31:2102-2106. - PubMed
    1. Burgess, D. S., R. W. Hastings, and T. C. Hardin. 2000. Pharmacokinetics and pharmacodynamics of cefepime administration by intermittent and continuous infusion. Clin. Ther. 22:66-75. - PubMed
    1. Bustad, A., D. Terziivanov, R. Leary, R. Port, A. Schumitzky, and R. Jelliffe. 2006. Parametric and nonparametric populations methods. Their comparative performance in analyzing a clinical dataset and two Monte Carlo simulation studies. Clin. Pharmacokinet. 45:365-383. - PubMed

Publication types